IPSC
Century Therapeutics, Inc.
There isn't enough reported data to score IPSC yet.
IPSC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Unavailable |
IPSC's revenue is currently healthy, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
IPSC PE Valuation
IPSC has no meaningful PE right now: it lost money over the past year.
IPSC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect IPSC's losses to shrink, with revenue declining.
IPSC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.64 | -$0.34 |
| Q2 2026 | -$0.93 | -$0.66 |
| Q1 2026 | -$1.14 | -$0.87 |
| Q4 2025 | -$0.14 | +$1.47 |
| Q3 2025 | -$0.30 | +$1.53 |
| Q2 2025 | -$0.27 | +$1.74 |
| Q1 2025 | -$0.27 | +$1.92 |
| Q4 2024 | -$1.61 | +$0.66 |
IPSC is still losing money, but far less than before: $0.64 per share over the past year, against $3.11 at its worst in late 2021.
IPSC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $109.2M | +12668% |
| Q4 2024 | $4.2M | +1457% |
| Q3 2024 | $791K | +434% |
| Q2 2024 | $771K | +679% |
| Q1 2024 | $855K | -50% |
| Q4 2023 | $268K | -49% |
| Q3 2023 | $148K | -93% |
| Q2 2023 | $99K | -93% |
IPSC's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | 68% | +3730 points |
| Q4 2024 | -893% | +15436 points |
| Q3 2024 | -4398% | +19674 points |
| Q2 2024 | -4508% | +30924 points |
| Q1 2024 | -3662% | -1797 points |
| Q4 2023 | -16329% | -9936 points |
| Q3 2023 | -24072% | -22645 points |
| Q2 2023 | -35431% | -33186 points |
IPSC's operating margin was 68% last quarter, up 3730 points from the same quarter a year ago, near the top of its range since 2022.
IPSC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.8M | +$3M |
| Q2 2026 | -$20.5M | +$7.4M |
| Q1 2026 | -$25.8M | +$9.3M |
| Q2 2025 | -$27.9M | -$312K |
| Q1 2025 | -$35.1M | -$4.3M |
| Q2 2024 | -$27.6M | -$3.8M |
| Q1 2024 | -$30.8M | +$3.4M |
| Q4 2023 | -$27.2M | +$2M |
IPSC has burned cash in almost every quarter: −$85M over the past year, against −$116M the year before.
IPSC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +661K shares |
| 1 year | +139% | +120M shares |
| 3 years | +248% | +147M shares |
| 5 years | +277% | +152M shares |
| Available history | +394% | +165M shares |
IPSC has 206M diluted shares, up 139% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IPSC Net Leverage
IPSC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IPSC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.8 | Neutral |
| Stochastic | 36.3 | Neutral |
IPSC's weekly RSI is 44 (neutral) and its Stochastic is 36 (neutral).
IPSC PE vs Healthcare Sector
IPSC has no meaningful PE right now: it lost money over the past year.
IPSC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.54 | 5.8% above |
| 20 week MA | $1.86 | 12% below |
| 50 week MA | $1.94 | 16% below |
| 100 week MA | $1.28 | 27% above |
| 200 week MA | $2.06 | 21% below |
IPSC's trend is mixed: it's above two of its five weekly moving averages, and 21% below its 200-week average.
IPSC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $22.8 | $18.2 | -20% |
| 2022 | $18.2 | $5.67 | -69% |
| 2023 | $5.67 | $3.32 | -41% |
| 2024 | $3.32 | $1.04 | -69% |
| 2025 | $1.04 | $1.09 | +4.8% |
| 2026 YTD | $1.09 | $1.63 | +50% |
IPSC is up 50% so far in 2026, after finishing lower in four of the previous five years.